Health and Biosciences: Targeted Regulatory Review

Published: January 2021
Last update: January 2021

Latest Updates

Since the launch of the Health and Bioscience Sector Regulatory Review Roadmap (Roadmap), Health Canada has made great strides in advancing work on the 16 identified initiatives. These updates to the Roadmap initiatives provide an overview of the work that has been undertaken, as well as the next steps to implement these commitments.

While the COVID-19 pandemic has impacted progress on Health Canada’s plans outlined in the Roadmap, it has also reinforced the need for regulatory agility and flexible approaches to health product oversight. In its response to the pandemic, Health Canada launched temporary emergency measures that helped companies in the health and biosciences sector bring urgently needed health products, including medical supplies for COVID-19, to market. These temporary measures have provided an opportunity to pilot many of the agile regulatory solutions planned as part of Health Canada’s Roadmap. Health Canada will use this experience to inform policy and regulatory development as implementation of Roadmap commitments continue.

Revised timelines for all regulatory initiatives can be found in Health Canada’s Forward Regulatory Plan.

Integration

Global Systems

Risk-based Approaches

Agile Frameworks

Health Canada's Novel Approaches

Additional details can be found on Health Canada's Program and Policy Initiatives and Novel Regulatory Approaches.

Regulatory reviews in other sectors

Related links

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: